Who
Stanley C. Erck
Director
Company insider
Files Form 4 as: Director, MaxCyte; President and CEO, Novavax; Director, BioCryst Pharmaceuticals; President & CEO, Intercell USA.
In numbers
- Trades disclosed
- 241
- Buys
- 15
- Sells
- 18
- Bought
- $743K
- Sold
- $51.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 16 Feb 2006
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 13 Aug 2025filed 13 Aug 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $137K100,000 at $1.37 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,790 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —29,210 at $0.00 | filing |
| 1 Nov 2024filed 5 Nov 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —47,689 at $0.00 | filing |
| 1 Nov 2024filed 5 Nov 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $1,90847,689 at $0.04 | filing |
| 1 Nov 2024filed 5 Nov 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $177K47,689 at $3.72 | filing |
| 2 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —21,607 at $0.00 | filing |
| 2 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $86421,607 at $0.04 | filing |
| 2 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $80K21,607 at $3.71 | filing |
| 1 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —26,082 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $1,04326,082 at $0.04 | filing |
| 1 Oct 2024filed 2 Oct 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $99K26,082 at $3.78 | filing |
| 4 Sep 2024filed 5 Sep 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —29,767 at $0.00 | filing |
| 4 Sep 2024filed 5 Sep 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code M | $1,19129,767 at $0.04 | filing |
| 4 Sep 2024filed 5 Sep 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $118K29,767 at $3.97 | filing |
| 3 Sep 2024filed 5 Sep 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —17,922 at $0.00 | filing |
News
MaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpMXCT · rttnews.com · 14 Oct 2026MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMXCT · manilatimes.net · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)NVAX · themarketsdaily.com · 11 Oct 2026Novavax (NASDAQ:NVAX) Sees Large Volume Increase – Should You Buy?NVAX · dailypolitical.com · 9 Oct 2026
0 headlines in the last 90 days name Stanley C. Erck; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.